Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Frontiers in pruritus research: scratching the brain for more effective itch therapy
Ralf Paus, … , Tamás Bíró, Martin Steinhoff
Ralf Paus, … , Tamás Bíró, Martin Steinhoff
Published May 1, 2006
Citation Information: J Clin Invest. 2006;116(5):1174-1186. https://doi.org/10.1172/JCI28553.
View: Text | PDF
Review Series Article has an altmetric score of 11

Frontiers in pruritus research: scratching the brain for more effective itch therapy

  • Text
  • PDF
Abstract

This Review highlights selected frontiers in pruritus research and focuses on recently attained insights into the neurophysiological, neuroimmunological, and neuroendocrine mechanisms underlying skin-derived itch (pruritogenic pruritus), which may affect future antipruritic strategies. Special attention is paid to newly identified itch-specific neuronal pathways in the spinothalamic tract that are distinct from pain pathways and to CNS regions that process peripheral pruritogenic stimuli. In addition, the relation between itch and pain is discussed, with emphasis on how the intimate contacts between these closely related yet distinct sensory phenomena may be exploited therapeutically. Furthermore, newly identified or unduly neglected intracutaneous itch mediators (e.g., endovanilloids, proteases, cannabinoids, opioids, neurotrophins, and cytokines) and relevant receptors (e.g., vanilloid receptor channels and proteinase-activated, cannabinoid, opioid, cytokine, and new histamine receptors) are discussed. In summarizing promising new avenues for managing itch more effectively, we advocate therapeutic approaches that strive for the combination of peripherally active antiinflammatory agents with drugs that counteract chronic central itch sensitization.

Authors

Ralf Paus, Martin Schmelz, Tamás Bíró, Martin Steinhoff

×

Figure 4

PARs play a key role in pruritus during neurogenic inflammation.

Options: View larger image (or click on image) Download as PowerPoint
PARs play a key role in pruritus during neurogenic inflammation.
(i) Try...
(i) Tryptase released from degranulated mast cells activates PAR2 at the plasma membrane of sensory nerve endings. (ii) Activation of PAR2 by tryptase, trypsins, kallikreins, or probably exogenous proteinases (bacteria, house dust mite) stimulates the release of calcitonin gene–related peptide (CGRP) and tachykinins, e.g., SP, from sensory nerve endings. (iii) CGRP interacts with the CGRP1 receptor to induce arteriolar dilation and hyperaemia. (iv) SP interacts with the neurokinin-1 receptor (NK1R) on endothelial cells of postcapillary venules to cause gap formation and plasma extravasation. Hyperaemia and plasma extravasation cause edema during inflammation. (v) SP may stimulate degranulation of mast cells, providing a positive-feedback mechanism. (vi) Tryptase degrades CGRP and terminates its effects. (vii) CGRP inhibits SP degradation by neutral endopeptidase and also enhances SP release, thereby amplifying its effects. (viii) Mediators from mast cells and other inflammatory cells stimulate the release of vasoactive peptides from sensory nerves and also sensitize nerves. (ix) At the spinal cord level, PAR2-induced intracellular Ca2+ mobilization leads to release of CGRP (and SP) from central nerve endings, thereby activating CGRP receptor (CGRPR) and NK1R to transit itch responses to the central nervous system. (x) During inflammation, PAR2 may be peripherally transported, thereby increasing receptor density and stimulation. Figure modified with permission from Nature Medicine (64, 125).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 6 patents
On 1 Facebook pages
Referenced in 3 Wikipedia pages
Mentioned in 1 Google+ posts
192 readers on Mendeley
See more details